>>Signaling Pathways>> GPCR/G protein>> Adrenergic Receptor>>Naftopidil (hydrochloride)

Naftopidil (hydrochloride) (Synonyms: KT-611 hydrochloride; BM-15275 hydrochloride)

Catalog No.GC44311

나프토피딜(염산염)(KT-611 염산염)은 선택적 알파1-아드레날린 수용체 길항제이며, 복제된 인간 α1a-, α1b- 및 α1d-아드레날린 수용체 아형에 대해 Kis가 각각 3.7 nM, 20 nM 및 1.2 nM입니다. 나프토피딜(염산염)은 항증식 효과가 있습니다. 나프토피딜(염산염)은 전립선 비대증 연구에 사용할 수 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

Naftopidil (hydrochloride) Chemical Structure

Cas No.: 1164469-60-6

Size 가격 재고 수량
25mg
US$67.00
재고 있음
50mg
US$127.00
재고 있음
100mg
US$240.00
재고 있음
250mg
US$535.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Naftopidil is an α1-adrenergic receptor antagonist that competitively inhibits α-adrenoceptor-mediated contractions induced by noradrenaline with pA2 values of 6.73-8.15 in various blood vessels from dog, rabbit, guinea pig, and rat. It binds to the cloned human α1-adrenergic receptors with Ki values of 3.7, 20, and 1.2 nM for α1A, α1B and α1D, respectively. Clinical formulations of naftopidil are used in the treatment of benign prostatic hyperplasia in Japan. Naftopidil also exhibits antiproliferative activity, inhibiting the growth of androgen-sensitive LNcaP cells and androgen-insensitive PC-3 cancer cell lines with IC50 values of 22.2 and 33.2 µM, respectively.

리뷰

Review for Naftopidil (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Naftopidil (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.